Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Gynaecol Oncol ; 29(5): 462-7, 2008.
Article in English | MEDLINE | ID: mdl-19051813

ABSTRACT

INTRODUCTION: We retrospectively evaluated the performance of preoperative computed tomographic (CT) colonography to detect tumor involvement of the rectosigmoid wall and predict the need for rectosigmoid resection in patients with primary ovarian cancer. METHODS: Thirty-three patients with primary ovarian cancer who underwent preoperative CT colonographic examination were evaluated. The images of the examination were analyzed and compared with the subsequent surgical findings. RESULTS: All abnormal findings (malignant infiltration of the rectosigmoid mucosa and extrinsic compression) revealed by conventional colonoscopy were correctly observed as extrinsic compression using CT colonography. The sensitivity, specificity, positive predictive value and negative predictive value of CT colonography for the prediction of rectosigmoid resection were 100%, 64.7%, 72.7%, and 100%, respectively. Though conventional colonoscopic examinations could not be completed in five patients because of the presence of extrinsic stenosis and occlusion at the sigmoid colon, CT colonography enabled the entire large bowel to be examined in these patients. CONCLUSIONS: This preliminary study showed that the CT colonographic examination is feasible and safe. CT colonography seems to have several advantages over conventional colonoscopy for the detection of rectosigmoid involvement in patients with advanced ovarian cancer. For confirmation of the efficacy of CT colonography, further large prospective studies are needed.


Subject(s)
Colon/diagnostic imaging , Ovarian Neoplasms/pathology , Rectal Neoplasms/diagnostic imaging , Rectal Neoplasms/secondary , Sigmoid Neoplasms/diagnostic imaging , Sigmoid Neoplasms/secondary , Tomography, X-Ray Computed , Adult , Aged , Female , Humans , Middle Aged , Retrospective Studies , Sensitivity and Specificity
2.
Int J Gynecol Cancer ; 17(5): 1172-8, 2007.
Article in English | MEDLINE | ID: mdl-17587317

ABSTRACT

We performed unilateral or bilateral nerve-sparing (UNS or BNS) radical hysterectomies combined with a parametrial excision in patients with locally advanced cervical cancer. The parametrial excision technique is characterized by a meticulous sharp dissection of the avascular plane outside the visceral fascia of the uterus and vagina under direct vision, providing an en bloc parametria and ensuring that all regional spread of the disease is contained within negative surgical margins. The aim of this study was to describe this surgical technique and to retrospectively evaluate the feasibility and the impact on early bladder function. From February 2005 to November 2006, 32 patients with FIGO stage IB-IIB cervical cancer, who had the tumor of more than 20 mm in diameter, underwent the UNS surgery or BNS surgery. A parametrial excision was performed in all the patients. The surgical procedure was safely completed in all the patients. Though 14 patients had tumor invasion to the parametria, none of the patients had a positive surgical margin in the parametrium. The bladder function of patients in the UNS group immediately after surgery was more damaged than that in the BNS group. However, all the patients in both groups recovered spontaneous voiding with no need of self-catheterization during the perioperative periods. This preliminary study showed that the surgical technique is feasible and safe. For confirmation of the efficacy of this technique, further large prospective studies are needed.


Subject(s)
Autonomic Pathways/surgery , Hysterectomy/methods , Pelvis/surgery , Uterine Cervical Neoplasms/surgery , Adult , Aged , Female , Humans , Middle Aged , Pelvis/innervation , Treatment Outcome , Urinary Bladder/physiopathology
3.
Int J Gynecol Cancer ; 17(5): 1150-4, 2007.
Article in English | MEDLINE | ID: mdl-17367323

ABSTRACT

Hepatoid adenocarcinoma is characterized histologically by neoplastic epithelial cells that resemble hepatocellular carcinoma (HCC) and produce alpha-fetoprotein (AFP). We describe a case of hepatoid adenocarcinoma of the uterus that, unlike any other previously reported case, was strictly confined to the cervix. A cervical biopsy demonstrated poorly differentiated adenocarcinoma, and hysterectomy and bilateral salpingo-oophorectomy were subsequently performed. Histologically, the lesion consisted of solid sheets of hepatoid cells accompanied with areas of endometroid adenocarcinoma. The tumor cells showed strong and diffuse cytoplasmic immunoreactivity with AFP in both medullary and adenocarcinoma components. Metastases to bilateral pelvic lymph nodes were detected 12 months after surgery. Since undergoing total pelvic irradiation, the patient has been alive and in full remission for 22 months. To our knowledge, this is the first report of primary hepatoid adenocarcinoma of the uterine cervix.


Subject(s)
Adenocarcinoma/diagnosis , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Uterine Cervical Neoplasms/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Female , Humans , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgery , alpha-Fetoproteins/analysis
4.
Eur J Gynaecol Oncol ; 23(4): 281-6, 2002.
Article in English | MEDLINE | ID: mdl-12214723

ABSTRACT

PURPOSE OF INVESTIGATION: To evaluate the impact on disease free survival (DFS) with maintenance chemotherapy following complete surgery and adjuvant chemotherapy in patients with stage Ic and II epithelial ovarian cancer by a retrospective study. METHODS: One hundred and forty patients with stage Ic and stage II epithelial ovarian cancer were classified into three groups according to the modality of maintenance chemotherapy (no therapy, oral or intravenous administration of anti-cancer drugs). DFS was compared among the three groups, and independent predictive factors for relapse were analyzed. RESULTS: There were no statistically significant differences in DFS among the three groups for either stage Ic or II cancers, stage Ic and stage II. Multivariate analysis revealed that independent predictive factors for relapse were stage II (p = 0.004) in all patients and less than three cycles of adjuvant chemotherapy in stage II patients (p = 0.015). CONCLUSION: Maintenance chemotherapy had no impact on DFS in patients with stage Ic or II epithelial ovarian cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/mortality , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/mortality , Adenocarcinoma, Clear Cell/mortality , Adenocarcinoma, Mucinous/mortality , Adolescent , Adult , Aged , Carboplatin/administration & dosage , Cisplatin/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cystadenocarcinoma, Papillary/mortality , Disease-Free Survival , Drug Administration Schedule , Drug Resistance, Neoplasm , Etoposide/administration & dosage , Female , Humans , Ifosfamide/administration & dosage , Japan , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Neoplasm Staging , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Paclitaxel/administration & dosage , Prognosis , Retrospective Studies
5.
J Lab Clin Med ; 138(3): 177-85, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11528370

ABSTRACT

Systemic inhibition of nitric oxide synthase (NOS) in streptozotocin-induced (STZ-induced) diabetic rats results in decreases in glomerular filtration rate (GFR) and renal plasma flow (RPF) and an increase in renal vascular resistance (RVR). However, the exact isoform of NOS involved in diabetic renal hyperfiltration has not been determined. This study was conducted to clarify whether NO derived from neuronal NOS is involved in diabetic renal hyperfiltration when using a selective inhibitor of neuronal NOS, 7-nitro indazole (7-NI). Continuous infusion of NG-nitro-L -arginine methyl ester (L-NAME) at 5 microg/kg/min ameliorated renal hyperfiltration, decreased RPF, and increased RVR in diabetic rats without affecting the mean arterial pressure (MAP). 7-NI administered intraperitoneally in diabetic rats significantly reduced GFR without affecting MAP, but the renal hyperfiltration was still observed after the administration of 7-NI. The combined administration of L-NAME after 7-NI caused a further decrease in GFR in diabetic rats and ultimately resulted in normalization of GFR. 7-NI did not change any parameters of renal hemodynamics in control rats. Urinary excretion of nitrite/nitrate and cyclic guanosine monophosphate was significantly increased in diabetic rats over values found in control rats. Our results suggested that a local inhibition of NO in the kidney was involved in the amelioration of diabetic renal hyperfiltration and that NO derived from neuronal NOS is involved, at least in part, in renal hyperfiltration in STZ-induced diabetic rats.


Subject(s)
Diabetes Mellitus, Experimental/enzymology , Enzyme Inhibitors/pharmacology , Glomerular Filtration Rate/drug effects , Nitric Oxide Synthase/antagonists & inhibitors , Animals , Cyclic GMP/urine , Drug Synergism , Hemodynamics/drug effects , Indazoles/pharmacology , Infusions, Intravenous , Injections, Intraperitoneal , Male , NG-Nitroarginine Methyl Ester/pharmacology , Nitrates/urine , Nitric Oxide Synthase Type I , Nitrites/urine , Rats , Rats, Sprague-Dawley , Renal Plasma Flow/drug effects , Vascular Resistance/drug effects
6.
Hum Reprod ; 16(6): 1274-7, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11387305

ABSTRACT

This study compared subsequent pregnancy outcome in patients with complete and partial hydatidiform moles. Among 1052 patients with molar pregnancy (complete mole, 801; partial mole, 251) monitored at Chiba University Hospital between 1981 and 1999, 891 patients (84.7%) had spontaneous resolution of human chorionic gonadotrophin (HCG) after mole evacuation, and 161 patients (15.3%) required chemotherapy. Of the 891 patients, 438 (49.2%) had 650 subsequent pregnancies. The pregnancy outcome was not significantly different in patients with complete and partial moles, and was comparable with that in the general Japanese population. The incidence of repeat molar pregnancy in patients with complete and partial mole (1.3 and 1.5% respectively) was 5-fold higher than that of the general population, while no increased risk of persistent gestational trophoblastic tumour (GTT) associated with later molar pregnancy was observed. During HCG follow-up, 10 patients (1.1%) developed secondary high-risk GTT between 14 and 54 months after mole evacuation. The incidence of high-risk GTT in patients with and without subsequent pregnancies was 0.46% (2/438) and 1.8% (8/453) respectively (P = 0.1243). In conclusion, patients with complete and partial mole can anticipate a normal future reproductive outcome, and pregnancies after experiencing hydatidiform mole may not affect the development of high-risk GTT.


Subject(s)
Chorionic Gonadotropin/blood , Hydatidiform Mole/surgery , Pregnancy Outcome , Adolescent , Adult , Female , Humans , Hydatidiform Mole/complications , Hydatidiform Mole/drug therapy , Middle Aged , Pregnancy , Recurrence , Risk Factors , Trophoblastic Neoplasms/epidemiology , Trophoblastic Neoplasms/etiology , Uterine Neoplasms/epidemiology , Uterine Neoplasms/etiology
7.
Obstet Gynecol ; 97(3): 431-4, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11239651

ABSTRACT

OBJECTIVE: To evaluate the efficacy of adjuvant hysterectomy with chemotherapy for women with low-risk gestational trophoblastic disease. METHODS: One hundred fifteen consecutive Japanese women (16-52 years old) with low-risk gestational trophoblastic disease (46 with metastatic disease and 69 without) were treated initially with single-agent chemotherapy (etoposide in 85, methotrexate in 27, and actinomycin D in three) with or without adjuvant hysterectomy, and 97 patients (84.3%) achieved primary remission with those treatments. Eight women (9.4%) treated with etoposide required other regimens because of drug resistance or toxicities. The total dose of etoposide given to achieve primary remission was analyzed in 77 women who received etoposide alone or with adjuvant hysterectomy. RESULTS: In 34 women with metastatic disease, the mean (+/- standard deviation [SD]) total dose of etoposide was not significantly different with and without adjuvant hysterectomy (2857 +/- 842 mg versus 2815 +/- 815 mg; P =.957; Mann-Whitney U test). However, in 43 women without metastases, the total dose of etoposide was significantly less in those who had adjuvant hysterectomies than in those who did not (1750 +/- 635 mg versus 2545 +/- 938 mg; P <.05; Mann-Whitney U test). CONCLUSION: Adjuvant hysterectomy decreased the total dose of etoposide given to achieve primary remission in women with nonmetastatic, low-risk gestational trophoblastic disease. If the lesions of gestational trophoblastic disease are confined to the uterus and the woman has no desire to preserve fertility, she should be informed of adjuvant hysterectomy as a treatment option.


Subject(s)
Antineoplastic Agents/therapeutic use , Hysterectomy , Trophoblastic Neoplasms/drug therapy , Trophoblastic Neoplasms/surgery , Uterine Neoplasms/drug therapy , Uterine Neoplasms/surgery , Adolescent , Adult , Chemotherapy, Adjuvant , Dactinomycin/therapeutic use , Etoposide/therapeutic use , Female , Humans , Methotrexate/therapeutic use , Middle Aged , Pregnancy , Treatment Outcome
8.
Toxicol Appl Pharmacol ; 169(2): 151-8, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11097867

ABSTRACT

Our study was designed to clarify whether renal functional reserve (RFR) was impaired in rats chronically treated with oral low-dose cadmium (Cd). Rats (n = 15) were treated with 1 ppm of cadmium chloride added to drinking water. We measured RFR (representing the ability to increase glomerular filtration rate [GFR] and renal plasma flow [RPF] in response to infusion of glycine) at 2 and 10 months after initiation of exposure to Cd. Urinary excretion of Cd was significantly higher in 10-month Cd-treated rats than in age-matched control rats (provided with distilled water only). Weight gain was noted in Cd-treated rats, which was identical to that in age-matched control rats. Urinary volume and urinary excretions of sodium, protein, and glucose were similar in the two groups. There were no differences in the basal mean arterial pressure (MAP) and renal hemodynamics between 2-month Cd-treated and age-matched control rats. Infusion of glycine resulted in significant increases in GFR and RPF and a significant reduction in renal vascular resistance (RVR) in both 2-month Cd-treated and age-matched control rats (control, GFR: 133 +/- 10%, RPF: 148 +/- 8%; 2-month Cd-treated rats, GFR: 152 +/- 12% and RPF: 154 +/- 7%). The basal MAP and renal hemodynamics in 10-month Cd-treated rats were also identical to those in age-matched control rats. Infusion of glycine significantly increased GFR in 10-month control rats (132 +/- 15%), but not in 10-month Cd-treated rats (98 +/- 11%), but did not change MAP, RPF, and RVR in both groups. In addition to age-related pathological changes, mild renal interstitial edema and degenerative mitochondria with diminished matrix density and loss of the cristae in the proximal tubular cells were more frequent in 10-month Cd-treated rats. Our results suggest that long-term oral intake of low-dose Cd in rats exacerbate age-related impairment of renal functional reserve and degeneration of the proximal tubular epithelial cells.


Subject(s)
Aging/physiology , Cadmium/toxicity , Kidney/physiology , Animals , Blood Pressure/drug effects , Body Weight/drug effects , Glomerular Filtration Rate/drug effects , Glomerular Filtration Rate/physiology , Hematocrit , Kidney/drug effects , Kidney/ultrastructure , Male , Microscopy, Electron , Rats , Rats, Sprague-Dawley , Renal Plasma Flow/drug effects , Urodynamics/drug effects
9.
Gynecol Oncol ; 78(1): 28-31, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10873405

ABSTRACT

OBJECTIVES: The goal of this study was to evaluate the efficacy, toxicity, and survival of patients with high-risk gestational trophoblastic tumors (GTTs) treated with a methotrexate-etoposide-actinomycin D (MEA) regimen without cyclosphosphamide or vincristine. METHODS: Thirty-nine consecutive patients with high-risk GTTs (28 were defined high risk by WHO criteria) were treated with primarily the MEA regimen. Among them, 27 patients had received no prior chemotherapy and 12 had received prior chemotherapy. Survival, causes of treatment failure, and toxicity were analyzed retrospectively. RESULTS: After treatment with the MEA regimen, 29 of 39 patients achieved primary remission (74.4%), 8 developed resistance (20.5%), and 2 died of widespread metastases and chemotherapy-related toxicity. All 8 patients who developed resistance were treated with high-dose 5-fluorouracil and actinomycin D (FA); 6 were salvaged and 2 died of refractory disease. Three patients relapsed; 2 were controlled with FA or cisplatin-based chemotherapy and 1 who refused further treatment died. The disease-free survival rate was 87%. WHO grade 4 leukocytopenia and thrombocytopenia with the MEA regimen occurred in 5.3 and 6.4%, respectively, of the cycles; other toxic effects were acceptable and manageable. CONCLUSIONS: At present, MEA chemotherapy (without cyclophosphamide or vincristine) is our treatment of choice for patients with high-risk GTT. Its toxicity is predictable and manageable. For patients who become resistant to MEA, new salvage chemotherapy regimens are needed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Trophoblastic Neoplasms/drug therapy , Uterine Neoplasms/drug therapy , Adult , Dactinomycin/administration & dosage , Disease-Free Survival , Etoposide/administration & dosage , Female , Humans , Methotrexate/administration & dosage , Middle Aged , Pregnancy , Risk Factors , Salvage Therapy , Treatment Outcome , Trophoblastic Neoplasms/pathology , Uterine Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...